TREA

98179729 - ZILBRYSQ

Follow

Information

  • Trademark
  • 98179729
  • Serial Number
    98179729
  • Filing Date
    September 14, 2023
    8 months ago
  • Transaction Date
    May 29, 2024
    10 days ago
  • Status Date
    May 16, 2024
    23 days ago
  • Published for Opposition Date
    June 18, 2024
    9 days from now
  • Location Date
    May 16, 2024
    23 days ago
  • Status Code
    681
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    GRAJEDA, HECTOR M
  • Attorney Docket Number
    TM23-0261
    Attorney Name
    Kumiko Ide
  • Owners
Information
Mark Drawing Code
4
Mark Identification
ZILBRYSQ
Case File Statements
  • GS0051: Pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory disorder, a wound, a burn, an autoimmune disorder, a pulmonary disorder, a cardiovascular disorder, a neurological disorder, a kidney-related disorder, a diabetes-related disorder, an ocular disorder, and a pregnancy-related disorder; Pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, the nervous system, the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical preparations for the treatment of fibrotic and inflammatory disorders; Pharmaceutical preparations for use in dermatology, nephrology, hepatology, rheumatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations as anti-viral, anti-bacterial, or anti-fungal agents
  • GS0101: Syringes for injections; Syringes for medical purposes; Syringes for medical purposes sold empty which may be filled with pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory indication, a wound, a burn, an autoimmune indication, a pulmonary indication, a cardiovascular indication, a neurological indication, a kidney-related indication, a diabetes-related indication, an ocular indication, and a pregnancy-related indication
Case File Event Statements
  • 9/18/2023 - 8 months ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 10/3/2023 - 8 months ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 12/8/2023 - 6 months ago
    3 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 4/30/2024 - a month ago
    4 - ASSIGNED TO LIE Type: ALIE
  • 4/30/2024 - a month ago
    5 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/30/2024 - a month ago
    6 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 5/8/2024 - a month ago
    9 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 5/8/2024 - a month ago
    7 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/8/2024 - a month ago
    8 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 5/8/2024 - a month ago
    10 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 5/10/2024 - 29 days ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 5/10/2024 - 29 days ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 5/10/2024 - 29 days ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 5/13/2024 - 26 days ago
    14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 5/29/2024 - 10 days ago
    15 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP